Re: SYN flying into Sept..
Actually SYN is the best performing among cos "owned" by Kirk so far this year. He bought 6 million shares during the last secondary offering at $1 to add to his already large position and I followed him to establish my initial position and had added substantially since. SYN has the immediate catalyst (partner of Trimesta with a large pharma for MS) and immediate and long-term catalysts for the other infectious drugs and whooping cough. It is simply incredible for a small biotech with such a deep pipeline. Any one of these potential development could be a blockbuster in sales, when approved. I believe this is the best kept secret among all companies Kirk has invested in. Since it is totally under the radar, its potential price appreciation will be multifold, once discovered by WS. I believe one of the reasons this is still a stock under $3 is the worry of many SYN may go for a secondary offering again as its cash position is somewhat limited. However I do believe it can fund its drug development once a partner for Trimesta is announced with upfront payment. In fact it may even sell tremesta outright for a handsome sum, since it is really a legacy drug which has been funded by outside source. In that case its need for a secondary offering will be greatly diminished. CEO Riley has mentioned in so many words that negotiations for partnership has been ongoing with many interested pharmas. While I own substantial shares of XON and ZIOP, SYN has performed far exceeding those two in my portfolio. In fact SYN is the one that has kept my confidence in Kirk's investment acumen! I think the possibility for Riley or Kirk will sell SYN for $6 is practically nil.